Expert Insights on Pooled Safety Data from the PRONTO and VI

Vaishali Sanchorawala, MD, provides insights on the pooled safety analysis of data from phase 1 to 3 trials, including PRONTO and VITAL, which investigated the use of birtamimab in patients with light chain (AL) amyloidosis.

Related Keywords

United States , American , Vaishali Sanchorawala , Heather Landau , Jeffrey Zonder , Peer Exchange , American Society Of Hematology , American Society , Light Chain Amyloidosis , Al Amyloidosis , Andromeda , Daratumumab , Vital , Pronto , Affirm Al , Nexicart 1 , Amyloid Deposits , Cd 38 Directed Monoclonal Antibodies , Cardiac Involvement , Mayo Cardiac Staging , Stem Cell Transplant , Remission , Duration Of Therapy , Diagnosis , Unmet Needs , Managing Al Amyloidosis , Treating Al Amyloidosis , Nxc 201 , Cart Therapy , Amyloidosis Diagnosis , Prognosis , Mortality ,